Argent Biopharma Ltd (ASX: RGT) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Argent Biopharma Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $8.14 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 54.27 million
Earnings per share -0.474
Dividend per share N/A
Year To Date Return -68.42%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Argent Biopharma Ltd (ASX: RGT)
    Latest News

    a woman
    ⏸️ Investing

    Why BOD Australia Ltd jumped 40% in a day

    This company enjoyed massive gains on Thursday. Here’s more…

    Read more »

    a woman
    ⏸️ Investing

    Why these 4 ASX shares have dropped lower today

    The Qantas Airways Limited (ASX:QAN) share price is one of four dropping lower on Thursday. Here’s why…

    Read more »

    a woman
    ⏸️ Investing

    Here are 2017's best performing ASX pot stocks

    Australia’s pot stocks have been a hot topic this year. And some have proved very lucrative for shareholders.

    Read more »

    a woman
    ⏸️ Investing

    Are the ASX pot stocks running out of puff?

    It hasn’t been a great start to the month for ASX pot stocks. Here’s why…

    Read more »

    a woman
    ⏸️ Investing

    Medical marijuana stocks are smoking hot right now

    The Auscann Group Holdings Ltd (ASX:AC8) share price is one of six in the medical marijuana industry that going gangbusters…

    Read more »

    a woman
    ⏸️ Investing

    Why MGC Pharmaceuticals Ltd shares jumped 11% higher

    The MGC Pharmaceuticals Ltd (ASX:MXC) share price has had a solid start to the week. Here’s why…

    Read more »

    a woman
    ⏸️ Investing

    What's the best ASX pot stock to buy?

    It’s hard to imagine a company dealing in a cash crop not making money. So let’s look at pot stocks…

    Read more »

    a woman
    ⏸️ Investing

    Australian pot stocks: November update

    The Auscann Group Holdings Ltd (ASX:AC8) share price is one of a number going nuts over the last few months…

    Read more »

    a woman
    ⏸️ Investing

    MGC Pharmaceuticals Ltd shares have doubled in value in a month

    The MGC Pharmaceuticals Ltd (ASX:MXC) share price is up 7% today, taking its one-month gain to over 100%. Here’s why…

    Read more »

    a woman
    ⏸️ Investing

    Pot stocks are flying high: Here's what you need to know

    The Auscann Group Holdings Ltd (ASX:AC8) share price and the Cann Group Ltd (ASX:CAN) share price have continued their strong…

    Read more »

    a woman
    ⏸️ Investing

    Why Auscann Group Holdings Ltd shares are up 29% this week

    The Auscann Group Holdings Ltd (ASX:AC8) share price is flying higher this week. Here’s why…

    Read more »

    a woman
    ⏸️ Investing

    MGC Pharmaceuticals Ltd shares surge higher on sales agreement

    The MGC Pharmaceuticals Ltd (ASX:MXC) share price has climbed higher again today after signing the first of its binding sales…

    Read more »

    RGT ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Argent Biopharma Ltd

    MGC Pharmaceuticals Ltd. engages in the production of medical marijuana. Its Endocannabinoid system covers all cells and nerves; it is the messenger of information flowing between immune system and the central nervous system. The company was founded by Nativ Segev on October 21, 2005 and is headquartered in Perth, Australia.

    RGT Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    24 Dec 2024 $0.15 $-0.01 -6.45% 4,289 $0.16 $0.16 $0.15
    23 Dec 2024 $0.16 $0.00 0.00% 155 $0.16 $0.16 $0.16
    20 Dec 2024 $0.16 $-0.02 -11.76% 56,564 $0.16 $0.16 $0.16
    19 Dec 2024 $0.17 $0.00 0.00% 2,788 $0.17 $0.17 $0.17
    18 Dec 2024 $0.17 $0.00 0.00% 85,389 $0.17 $0.18 $0.17
    17 Dec 2024 $0.17 $-0.01 -5.56% 37,648 $0.18 $0.18 $0.17
    16 Dec 2024 $0.18 $0.01 5.71% 33,084 $0.18 $0.18 $0.18
    13 Dec 2024 $0.18 $-0.02 -10.26% 63,991 $0.19 $0.19 $0.18
    12 Dec 2024 $0.20 $-0.01 -5.00% 21,673 $0.20 $0.20 $0.19
    11 Dec 2024 $0.20 $0.01 5.26% 4,935 $0.20 $0.20 $0.20
    10 Dec 2024 $0.19 $-0.01 -5.00% 13,544 $0.20 $0.20 $0.19
    09 Dec 2024 $0.20 $0.00 0.00% 1,339 $0.20 $0.20 $0.20
    06 Dec 2024 $0.21 $-0.02 -9.09% 146 $0.21 $0.21 $0.21
    05 Dec 2024 $0.22 $0.01 4.65% 2,461 $0.22 $0.23 $0.22
    04 Dec 2024 $0.22 $-0.03 -12.50% 3,863 $0.22 $0.22 $0.21
    03 Dec 2024 $0.24 $-0.01 -4.00% 2,640 $0.24 $0.24 $0.24
    02 Dec 2024 $0.25 $-0.02 -7.41% 8,705 $0.27 $0.27 $0.25
    29 Nov 2024 $0.27 $0.02 8.00% 2,100 $0.25 $0.27 $0.25
    28 Nov 2024 $0.25 $0.00 0.00% 6,220 $0.26 $0.26 $0.25
    27 Nov 2024 $0.25 $0.01 4.17% 19,907 $0.26 $0.26 $0.25

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    15 Oct 2024 Roby Zomer Buy 4,000,000 $1,640,000
    As advised by the company.
    10 Sep 2024 Roby Zomer Buy 1,258,500 $503,400
    Off-market trade.
    28 Mar 2024 Layton Mills Issued 120,000 $49,200
    Issue of options.
    28 Mar 2024 Daniel Robinson Issued 120,000 $49,200
    Issue of options.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Layton Patrick Mills Non-Executive Director Jun 2023
    Mr. Mills is an experienced life-sciences executive, having worked in the biotechnology and life sciences industries for over 15 years, developing experience across human and animal health in pharmaceutical and consumer healthcare. Mr Mills is also the founder and Managing Director of Subgenix Lifesciences, an early-stage biotechnology Company using conventional drug development strategies to unlock the broader therapeutic potential of psychedelic compounds for rare and underserved health needs. He has international business experience having been involved in corporate business activities across Europe, Asia and North America, including government-led trade incentives with the Canberra Business Chamber.
    Mr Brett Anthony Mitchell Executive ChairmanExecutive Director Apr 2013
    Mr Mitchell has over 25 years of experience in the venture capital, equity capital markets, technology and resources sectors. He has been involved in the founding, financing and management of both private and publicly listed companies, and was instrumental in the successful LSE listing for MGC Pharma in February 2021.
    Mr Daniel Robinson Non-Executive Director Dec 2023
    Mr Robinson has been appointed as a Non-Executive Director of the Company effective immediately. Mr Robinson has over 20 years of experience in a broad range of corporate roles across stockbroking, corporate advisory, investor relations and governance. He is an experienced Company Secretary and Director of both private and listed companies. Additionally, Mr Robinson is a Member of the Australian Institute of Company Directors.
    Mr Nativ Segev Non-Executive Director Feb 2016
    Mr Segev has over 10 years of experience in implementation, legislation and lobbying in the global Medical Cannabis industry, combined with over 15 years of experience in diverse executive roles.
    Mr Roby Reuven Zomer Chief Executive OfficerManaging Director Feb 2016
    Mr Zomer is an executive with experience in the biopharmaceutical and biotech industries. As the CEO of the company, Roby has demonstrated has driven strategic growth, managed financial operations, and ensured compliance with industry-specific standards. He also served as the Chairman of the Board for Graft Polymer, overseeing the implementation of advanced polymer solutions in the Biotech, Automotive and Recycling sectors. Roby's entrepreneurial background includes founding and leading Green City Urban Recycling, a pioneering Israeli company focused on biofuel production. His innovative work in this field contributed to national energy independence initiatives and led to the company's acquisition by Rafael Advanced Defense Systems. With an industrial engineering and management foundation, Roby Zomer brings a blend of technical and strategic skills to his professional endeavors.
    Mr Rowan Harland Company Secretary Mar 2023
    -
    Rowan Harland Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Oak Capital Partners Llc 8,370,718 17.29%
    Group Capital Llc 3,913,812 8.09%
    David Safren 3,405,016 7.03%
    Citicorp Nominees Pty Limited 2,301,084 4.75%
    Shlomie Bierman 2,230,874 4.61%
    Computershare Clearing Pty Ltd <Ccnl Di A/C> 2,099,936 4.34%
    Isamar Margareten 1,956,906 4.04%
    Mr Shachar Shimony 1,933,000 3.99%
    Yaakov Safren 1,643,802 3.40%
    Jacob Goldstein 1,623,072 3.35%
    Yoram Drucker 1,604,664 3.32%
    Yosef Safren 1,565,526 3.23%
    Shalom Safren 1,448,112 2.99%
    Bioheka Limited 1,258,500 2.60%
    Mrs Yifat Steuer 1,117,194 2.31%
    Eliron Yaron 750,000 1.55%
    A1 Invest Llc 625,000 1.29%
    Mr Itay David Nissim 600,000 1.24%
    Mr Amir Polak 592,626 1.22%
    Joseph Schwartz 547,934 1.14%

    Profile

    since

    Note